← All stories
Markets
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.
Covered by 1 outlet
All coverage · 1 article